(FM) Hematología
Departamento académico
Fermín
Sánchez-Guijo Martín
Publicacións nas que colabora con Fermín Sánchez-Guijo Martín (16)
2023
2022
-
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Frontiers in Immunology, Vol. 13
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)
Trials, Vol. 22, Núm. 1
-
Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
ERJ Open Research, Vol. 7, Núm. 2, pp. 00773-2020
-
Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis
Journal of Translational Medicine
2020
-
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study
EClinicalMedicine, Vol. 25
-
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)
Frontiers in Immunology
-
Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
Journal of Translational Medicine, Vol. 18, Núm. 1
-
Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research
Cytotherapy, Vol. 22, Núm. 1, pp. 1-5
2019
-
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Frontiers in Immunology, Vol. 10, Núm. JUN
2018
2016
2014
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2011
-
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial
Haematologica, Vol. 96, Núm. 7, pp. 1072-1076